

Global Primary Biliary Cholangitis Therapeutics Market Size study, by Drug Type (Primary Drug, Secondary Drug), by Distribution Channel and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G11C05966B16EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G11C05966B16EN

Abstracts

Global Primary Biliary Cholangitis (PBC) Therapeutics Market is valued at approximately USD 0.73 billion in 2023 and is projected to exhibit a robust compound annual growth rate (CAGR) of 7.50% over the forecast period 2024-2032. Primary biliary cholangitis is an autoimmune liver disease that leads to progressive destruction of bile ducts, chronic cholestasis, and eventually liver failure if untreated. Despite being a rare disorder, its high burden on liver transplantation queues, combined with an evolving understanding of its immunological and genetic etiology, has significantly increased demand for precise and effective treatment options. Current therapies—particularly ursodeoxycholic acid and obeticholic acid—serve as primary pharmaceutical interventions, but novel agents under development aim to fill therapeutic gaps in treatment-resistant patients.

Recent strides in clinical hepatology and the rise in early diagnosis owing to routine liver enzyme testing have accelerated treatment initiation rates. This shift is supported by stronger clinical guidelines that emphasize early intervention to delay cirrhosis progression. Pharmaceutical firms are increasingly focusing on secondary therapies—especially those targeting pruritus, fatigue, and metabolic complications of PBC—to round out holistic treatment regimens. As a result, the market has seen a growing emphasis on bile acid modulators, fibrates, and immunomodulatory agents, with promising trials underway that may redefine the standard of care. However, patient adherence, drug side-effect profiles, and limited therapeutic efficacy in advanced cases still hinder clinical success and long-term outcomes.

Regulatory incentives for orphan diseases, alongside strategic R&D collaborations and accelerated approval pathways, are creating fertile ground for innovation. Major pharmaceutical companies are actively investing in this niche domain, with pipelines featuring PPAR agonists, FXR agonists, and novel bile acid analogs. Furthermore, improved disease awareness campaigns led by patient advocacy groups, enhanced reimbursement schemes, and access to specialty liver clinics are helping to bring these therapies closer to patients. Diagnostic and biomarker advancements are further enabling more nuanced disease staging and individualized treatment planning, paving the way for precision hepatology.

Geographically, North America dominates the PBC therapeutics landscape, largely owing to robust R&D infrastructure, high diagnostic rates, and favorable regulatory support from agencies such as the FDA. Europe follows closely, with countries like Germany and the UK exhibiting strong adoption of newer therapies through national health services. The Asia Pacific region is expected to register the fastest CAGR due to expanding access to healthcare, increasing awareness of autoimmune liver diseases, and rising demand for advanced treatment options in countries like Japan, China, and South Korea. Latin America and the Middle East & Africa are anticipated to gain traction gradually as diagnostic networks and specialist care centers become more accessible.

Major market player included in this report are:

Intercept Pharmaceuticals, Inc.

GlaxoSmithKline plc

Novartis AG

AbbVie Inc.

Dr. Falk Pharma GmbH

Zydus Lifesciences Limited

Ipsen Biopharmaceuticals, Inc.

Gilead Sciences, Inc.

Merck & Co., Inc.

Bristol-Myers Squibb Company

Lupin Pharmaceuticals, Inc.

Sanofi S.A.

AstraZeneca plc

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

The detailed segments and sub-segment of the market are explained below:

By Drug Type

Primary Drug

Secondary Drug

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET EXECUTIVE SUMMARY

- 1.1. Global PBC Therapeutics Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drug Type
 - 1.3.2. By Distribution Channel
- 1.4. Key Trends
- 1.5. Reimbursement & Orphan Incentives Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL PBC THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Drug Availability
 - 2.3.3.2. Manufacturing & Cold-Chain Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Payer & Patient Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Clinical Guidelines & Early Diagnosis
 - 2.3.4.2. Technological Advancements (Biomarkers)
 - 2.3.4.3. Patient Awareness & Advocacy
 - 2.3.4.4. Reimbursement & Access Programs
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL PBC THERAPEUTICS MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Early Diagnosis via Routine Liver Enzyme Testing
- 3.1.2. Clinical Guideline Emphasis on Early Intervention
- 3.1.3. Orphan Drug Incentives & Accelerated Approvals

3.2. Market Challenges

- 3.2.1. Patient Adherence & Side-Effect Profiles
- 3.2.2. Limited Efficacy in Advanced-Stage Disease

3.3. Market Opportunities

- 3.3.1. Novel PPAR/FXR Agonists & Bile Acid Analogs
- 3.3.2. Biomarker-Driven Precision Hepatology
- 3.3.3. Expanded Specialty Clinic & Advocacy Programs

CHAPTER 4. GLOBAL PBC THERAPEUTICS MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunity

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL PBC THERAPEUTICS MARKET SIZE & FORECASTS BY DRUG TYPE 2022-2032

5.1. Segment Dashboard

5.2. Global PBC Market: Primary vs. Secondary Drug Revenue Trend Analysis, 2022 & 2032 (USD Million)

- 5.2.1. Primary Drug
- 5.2.2. Secondary Drug

CHAPTER 6. GLOBAL PBC THERAPEUTICS MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL 2022-2032

- 6.1. Segment Dashboard
- 6.2. Global PBC Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)
 - 6.2.1. Hospital Pharmacies
 - 6.2.2. Retail Pharmacies
 - 6.2.3. Online Pharmacies

CHAPTER 7. GLOBAL PBC THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022-2032

- 7.1. North America PBC Market
 - 7.1.1. U.S. PBC Therapeutics Market
 - 7.1.1.1. By Drug Type breakdown size & forecasts, 2022-2032
 - 7.1.1.2. By Distribution Channel breakdown size & forecasts, 2022-2032
 - 7.1.2. Canada PBC Therapeutics Market
- 7.2. Europe PBC Therapeutics Market
 - 7.2.1. UK PBC Market
 - 7.2.2. Germany PBC Market
 - 7.2.3. France PBC Market
 - 7.2.4. Spain PBC Market
 - 7.2.5. Italy PBC Market
 - 7.2.6. Rest of Europe PBC Market
- 7.3. Asia Pacific PBC Therapeutics Market
 - 7.3.1. China PBC Market
 - 7.3.2. India PBC Market
 - 7.3.3. Japan PBC Market
 - 7.3.4. Australia PBC Market
 - 7.3.5. South Korea PBC Market
 - 7.3.6. Rest of Asia Pacific PBC Market
- 7.4. Latin America PBC Therapeutics Market
 - 7.4.1. Brazil PBC Market
 - 7.4.2. Mexico PBC Market
 - 7.4.3. Rest of Latin America PBC Market

7.5. Middle East & Africa PBC Therapeutics Market

7.5.1. Saudi Arabia PBC Market

7.5.2. South Africa PBC Market

7.5.3. Rest of Middle East & Africa PBC Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

8.1. Key Company SWOT Analysis

8.1.1. Intercept Pharmaceuticals, Inc.

8.1.2. GlaxoSmithKline plc

8.1.3. Novartis AG

8.2. Top Market Strategies

8.3. Company Profiles

8.3.1. Intercept Pharmaceuticals, Inc.

8.3.1.1. Key Information

8.3.1.2. Overview

8.3.1.3. Financial (Subject to Data Availability)

8.3.1.4. Product Summary

8.3.1.5. Market Strategies

8.3.2. AbbVie Inc.

8.3.3. Dr. Falk Pharma GmbH

8.3.4. Zydus Lifesciences Limited

8.3.5. Ipsen Biopharmaceuticals, Inc.

8.3.6. Gilead Sciences, Inc.

8.3.7. Merck & Co., Inc.

8.3.8. Bristol-Myers Squibb Company

8.3.9. Lupin Pharmaceuticals, Inc.

8.3.10. Sanofi S.A.

8.3.11. AstraZeneca plc

8.3.12. Takeda Pharmaceutical Company Limited

8.3.13. Teva Pharmaceutical Industries Ltd.

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

- 9.1.5. Publishing
- 9.2. Research Attributes

I would like to order

Product name: Global Primary Biliary Cholangitis Therapeutics Market Size study, by Drug Type (Primary Drug, Secondary Drug), by Distribution Channel and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G11C05966B16EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G11C05966B16EN.html>